Aastrom Biosciences Articles
Sanofi-Aventis’ riferminogen pecaplasmid fails Ph III endpoints; partner Vical’s shares decimated; provides opportunity for Aastrom?
23 September 2010
Confusion over stem cell research legislation n the USA creates opportunities, says Zacks analyst
26 August 2010
Showing 1-3 of 3 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
